FI933656A0 - 2,4-diaminokinazolinderivat, som foerstaerker antitumoeraktivitet - Google Patents

2,4-diaminokinazolinderivat, som foerstaerker antitumoeraktivitet

Info

Publication number
FI933656A0
FI933656A0 FI933656A FI933656A FI933656A0 FI 933656 A0 FI933656 A0 FI 933656A0 FI 933656 A FI933656 A FI 933656A FI 933656 A FI933656 A FI 933656A FI 933656 A0 FI933656 A0 FI 933656A0
Authority
FI
Finland
Prior art keywords
derivatives
foerstaerker
diaminoquinazole
antitumoeractives
som
Prior art date
Application number
FI933656A
Other languages
English (en)
Finnish (fi)
Other versions
FI933656A (fi
Inventor
Jotham W Coe
Anton F J Fliri
Takushi Kaneko
Eric R Larson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI933656A publication Critical patent/FI933656A/fi
Publication of FI933656A0 publication Critical patent/FI933656A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI933656A 1991-02-20 1993-08-19 2,4-diaminokinazolinderivat, som foerstaerker antitumoeraktivitet FI933656A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65792291A 1991-02-20 1991-02-20
PCT/US1992/000028 WO1992014716A1 (en) 1991-02-20 1992-01-08 2,4-diaminoquinazolines derivatives for enhancing antitumor activity

Publications (2)

Publication Number Publication Date
FI933656A FI933656A (fi) 1993-08-19
FI933656A0 true FI933656A0 (fi) 1993-08-19

Family

ID=24639196

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933656A FI933656A0 (fi) 1991-02-20 1993-08-19 2,4-diaminokinazolinderivat, som foerstaerker antitumoeraktivitet

Country Status (23)

Country Link
EP (1) EP0572437B1 (no)
JP (1) JPH06500117A (no)
KR (1) KR930703270A (no)
CN (1) CN1064271A (no)
AT (1) ATE121735T1 (no)
AU (1) AU655798B2 (no)
BR (1) BR9205645A (no)
CA (1) CA2101542A1 (no)
CZ (1) CZ387292A3 (no)
DE (2) DE69202243T2 (no)
DK (1) DK0572437T3 (no)
ES (1) ES2071484T3 (no)
FI (1) FI933656A0 (no)
HU (1) HUT64755A (no)
IE (1) IE920522A1 (no)
IL (1) IL100942A0 (no)
MX (1) MX9200675A (no)
NO (1) NO932954L (no)
NZ (1) NZ241627A (no)
PT (1) PT100132A (no)
WO (1) WO1992014716A1 (no)
YU (1) YU17092A (no)
ZA (1) ZA921911B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ES2049659B1 (es) * 1992-10-08 1994-10-16 Ici Plc Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE4429026C2 (de) * 1994-08-16 1995-11-16 Mueller Wolfgang Inlay-Entfernungsinstrumentarium für Totalendoprothese
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5932574A (en) * 1995-04-27 1999-08-03 Zeneca Limited Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1997020822A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EE05330B1 (et) 1999-11-05 2010-08-16 Astrazeneca Ab Kinasoliini derivaadid kui VEGF-i inhibiitorid
WO2001068615A1 (en) * 2000-03-13 2001-09-20 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
NZ521421A (en) 2000-04-07 2004-09-24 Astrazeneca Ab Quinazoline compounds
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
CN1984660B (zh) * 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
JP2007269629A (ja) * 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
JP2008505907A (ja) * 2004-07-06 2008-02-28 アンジオン バイオメディカ コーポレイション 癌治療を目的として肝細胞増殖因子およびｃ−ｍｅｔ活性を調整するキナゾリンモジュレーター
CN101287369A (zh) * 2005-01-03 2008-10-15 美瑞德生物工程公司 治疗脑癌的方法
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1963284A1 (en) * 2005-12-07 2008-09-03 NeuroSearch A/S Novel quinazoline-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels
CN101100466B (zh) 2006-07-05 2013-12-25 天津和美生物技术有限公司 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
US20090004185A1 (en) * 2007-01-11 2009-01-01 Wyeth Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
CA2691932A1 (en) * 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
WO2011140527A2 (en) * 2010-05-07 2011-11-10 California Institute Of Technology And The University Of Kansas Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase
WO2018212774A1 (en) * 2017-05-17 2018-11-22 Vanderbilt University Quinazoline compounds as modulators of ras signaling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
AU610328B2 (en) * 1987-12-03 1991-05-16 Smithkline Beckman Intercredit B.V. 2,4- diaminoquinazoline derivatives
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
CN1064271A (zh) 1992-09-09
IL100942A0 (en) 1992-11-15
FI933656A (fi) 1993-08-19
EP0572437B1 (en) 1995-04-26
BR9205645A (pt) 1994-06-07
ES2071484T3 (es) 1995-06-16
KR930703270A (ko) 1993-11-29
DK0572437T3 (da) 1995-07-03
EP0572437A1 (en) 1993-12-08
ZA921911B (en) 1993-08-19
WO1992014716A1 (en) 1992-09-03
HU9302384D0 (en) 1993-11-29
DE9290018U1 (de) 1993-10-14
ATE121735T1 (de) 1995-05-15
PT100132A (pt) 1993-05-31
DE69202243D1 (de) 1995-06-01
AU655798B2 (en) 1995-01-12
CA2101542A1 (en) 1992-08-21
NZ241627A (en) 1993-06-25
JPH06500117A (ja) 1994-01-06
NO932954D0 (no) 1993-08-19
NO932954L (no) 1993-08-19
IE920522A1 (en) 1992-08-26
MX9200675A (es) 1992-08-01
DE69202243T2 (de) 1995-08-31
YU17092A (sh) 1994-12-28
AU1184892A (en) 1992-09-15
HUT64755A (en) 1994-02-28
CZ387292A3 (en) 1994-04-13

Similar Documents

Publication Publication Date Title
FI933656A0 (fi) 2,4-diaminokinazolinderivat, som foerstaerker antitumoeraktivitet
FI932032A0 (fi) Kinazolinderivat foer oekande av antitumoeraktivitet
ATE109002T1 (de) Wasserlösliche antineoplastische taxolderivate.
DE59100656D1 (de) Bohrfutter.
DE69103503D1 (de) Adriamycinderivate.
YU39992A (sh) Derivati 2,4-diaminopirimidina
FI923290A0 (fi) Imidazo (2,1-b)bensotiazol-3 -acetamidderivat.
NO883070D0 (no) 4-aminosubstituerte 1,2-dihydroksynaftalin-derivater.
ZA891242B (en) 24r-scymnol,and preparation and use thereof
DE58903154D1 (de) 2,2-difluorcyclopropyl-derivate.
DE69011268D1 (de) Diflourobenzonitril Derivate.
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
DE68903983D1 (de) 1,6-diazaspiro(4,4)nonan-2,7-dion-derivate.
DE69113570D1 (de) Behandlungsmittel.
GR1001394B (el) Παράγωγα 4-[4-[4-(4-υδροξυφαινυλ)-1-πιπεραζινυλ] φαινυλ]-5-με?υλ3Η-1,2,4-τριαζολ-3-όνης.
DE59007923D1 (de) 1,2,3,4-Tetrahydro-5-nitro-pyrimidin-Derivate.
LV5739A4 (lv) 1-AzatricikloÚ7.2.03,8¾undec-2-en-2-karbonskabes atvasinajumi
ITRO910007A0 (it) Mandrino ad assorbimento di 30.000 hz
RU93054001A (ru) 2,4-диаминохиназолиновые производные, способ их получения фармацевтическая композиция, способ ингибирования р-гликопротеина
MA21976A1 (fr) Le robinet economiseur .

Legal Events

Date Code Title Description
FD Application lapsed